DURHAM, N.C., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received nearly $245,000 in a grant under the Patient Protection and Affordable Care Program Act of 2010 (PPACA). The award was given for the Company's qualified investments under Section 48D of the PPACA for the clinical development of Oxycyte® perfluorocarbon emulsion for traumatic brain injury (TBI) and spinal cord injury.
